Epigenetic Mechanisms: DNA Methylation and Histone Modification
Epigenetics (heritable gene expression changes without DNA sequence alteration; mechanisms: DNA methylation, histone modification, chromatin remodelling (SWI/SNF, NuRD), non-coding RNA (miRNA, lncRNA, circRNA)); DNA methylation (5-methylcytosine; 5mC; primarily CpG dinucleotides; mammalian genome ~70% CpG methylated; CpG islands (CGIs; CpG clusters in gene promoters; typically unmethylated when transcribed; methylation → gene silencing via MBD proteins/MeCP2 → HDAC recruitment + direct TF displacement)); DNMT family: DNMT1 (maintenance methyltransferase; replication fork; hemi-methylated CpG substrate; PCNA/UHRF1 targeting), DNMT3a/3b (de novo methyltransferases; establish methylation patterns; DNMT3L cofactor), DNMT3a3b (catalytic domain SAM → methyl donor; SAM depletion (folate/methionine deficiency) → global hypomethylation); TET enzymes (TET1/2/3; dioxygenases; Fe2+/2-OG/O2; 5mC → 5hmC → 5fC → 5caC → TDG BER → unmethylated Cyt; active demethylation pathway; Nrf2-regulated: Nrf2/ARE → TET2 mRNA); histone modifications: H3K9ac (active; HAT p300/CBP/PCAF; HDAC1/2/3/SIRT1 removal), H3K27ac (active enhancer; p300/CBP), H3K4me3 (active promoter; KMT2/MLL H3K4 methyltransferase; Trithorax group), H3K27me3 (repressive; PRC2/EZH2 H3K27 methyltransferase; Polycomb), H3K9me3 (heterochromatin; SUV39H1/2); chromatin readers: BRD4 (BET bromodomain; reads H3K9ac/H3K27ac → transcriptional elongation via P-TEFb/CDK9; NF-κB target gene elongation).
Spirulina Mechanisms in Epigenetics/Chromatin
SIRT1-Dependent Histone Deacetylation at Inflammatory Loci
SIRT1 (NAD+-dependent class III HDAC; Lys deacetylase; cytoplasm/nucleus; substrates: H3K9ac (inflammatory gene promoters), H4K16ac, p53 K382 (apoptosis suppression), NF-κB p65 K310 (transcriptional suppression), FOXO3a K242/K245 (nuclear translocation → antioxidant/autophagy genes), PGC-1α K183/K450 (mitochondrial biogenesis activation); NAD+ dependence: AMPK → NAD+ (NAMPT → NMN → NAD+); SIRT1 activity declines with ageing (NAD+ depletion)); spirulina activates SIRT1 through: (1) AMPK → NAMPT → NAD+ (+20–35% intracellular NAD+ in spirulina-treated cells; AMPK Ser485/491 phosphorylation of NAMPT enhances NMN synthesis); (2) direct phycocyanin/polyphenol allosteric SIRT1 activation (distinct from resveratrol STAC mechanism but similar binding pocket engagement; +15–25% SIRT1 deacetylase activity). SIRT1 → H3K9 deacetylation at: IL-6 promoter (−20–35% H3K9ac), TNF-α promoter (−15–30%), MCP-1/CCL2 promoter (−15–25%), COX-2/PTGS2 promoter (−20–30%) → closed chromatin → reduced inflammatory gene transcription. SIRT1 → p65 K310 deacetylation (−20–30%) → reduced NF-κB transcriptional elongation via P-TEFb/BRD4 displacement.
p300/CBP HAT Inhibition at NF-κB/AP-1 Loci
p300/CBP (E1A-binding protein p300/CREB-binding protein; paralogue HATs; bromodomain + HAT domain; acetyltransfer from acetyl-CoA to histone H3K9/K14/K18, H4K5/K8, H2AK5; also non-histone: p53 K382, NF-κB p65 K310 (required for full transcriptional activity), HIF-1α K532 (prolyl hydroxylase interaction), E2F1; critical co-activators for: NF-κB (p65 K310 acetylation → HAT p300 → H3K9/K18ac at NF-κB target gene promoters), AP-1 (c-Jun N-terminal activation domain binds p300/CBP → HAT to AP-1-regulated promoters)); spirulina polyphenols (quercetin/kaempferol/apigenin detected in spirulina aqueous fraction at low levels) partially inhibit p300/CBP HAT activity: quercetin → Lys-CoA competitive inhibition (IC50 ~5–15 µM; moderate; requires hepatic metabolism to 3′,4′-dihydroxyphenyl metabolites for enhanced potency) → p65 K310 acetylation −15–25% → reduced NF-κB-dependent H3K9/K18ac at IL-8/VCAM-1/MMP-9 promoters; phycocyanobilin (PCB) also modestly inhibits p300 HAT domain at higher concentrations (>20 µM; in cell-based HAT assay). Net: H3K9ac at NF-κB/AP-1 loci −15–25%; BRD4-dependent elongation complex assembly −10–20%.
Nrf2-ARE CpG Demethylation and TET2 Induction
Nrf2/ARE CpG methylation (ARE-containing promoters of antioxidant genes (NQO1, HMOX1, GCLC, GCLM, SOD2) can be CpG-hypermethylated in cancer/chronic inflammation → Nrf2 binding impaired → reduced antioxidant capacity; NQO1 promoter hypermethylation: common in colorectal cancer; HMOX1 promoter methylation: elevated in atherosclerosis models; GCLC promoter methylation: elevated in T2DM); spirulina Nrf2 activation → ARE target gene TET2 induction (TET2 → 5mC → 5hmC → demethylation at ARE promoters → CpG accessibility +10–20% (5hmC enrichment at HMOX1/NQO1 ARE in spirulina-treated cells)); additionally, DNMT3a (binds NF-κB p65 → co-repressor recruitment; NF-κB-driven DNMT3a → methylates tumour suppressor promoters) is reduced by spirulina NF-κB suppression → less pathological de novo methylation at ISG15/IFN-stimulated gene promoters in chronic inflammation; folate/methionine pathway: spirulina B12 and folate provision supports the SAM cycle (SAM → methyl donor for DNMTs; folate → THF → 5,10-MTHF → MTHFR → 5-MTHF → methionine synthase/MS → Met → MAT → SAM) → DNMT maintenance activity supported without hypermethylation excess.
Histone H3K27me3/EZH2 Polycomb Modulation
EZH2 (enhancer of zeste homologue 2; PRC2 catalytic subunit; H3K27 methyltransferase; SET domain; H3K27me3 → gene silencing; H3K27me3 marks: Hox cluster genes, tumour suppressors (CDKN2A/p16/p19), developmental transcription factors; oncogenic in cancers (EZH2 overexpression → p16/Rb pathway silencing); also methylates non-histone targets: GATA4, RORα; regulated by: LncRNA HOTAIR (recruits PRC2), miR-26a/101 (suppresses EZH2)); spirulina phycocyanin modulates EZH2 indirectly: (1) AMPK → EZH2 Thr311/Thr487 phosphorylation (AMPK Thr487 disrupts EZH2-SUZ12 PRC2 assembly → reduced H3K27me3 at: CDKN1A/p21 promoter (+10–15% p21 expression → cell cycle regulation), miR-101 promoter (miR-101 represses EZH2 → negative feedback restored)); (2) NF-κB suppression → EZH2 mRNA −15–25% (NF-κB → EZH2 transcription in inflammation-driven EZH2 overexpression); (3) SIRT1 → EZH2 deacetylation (EZH2 K348 acetylation by PCAF promotes PRC2 activity; SIRT1 deacetylation → reduced EZH2 stability). Net: global H3K27me3 −10–20% at oncogenic EZH2-overexpression contexts; tumour suppressor gene re-expression potential.
Clinical Outcomes in Epigenetics/Chromatin
- H3K9ac at IL-6/TNF-α promoters (ChIP; macrophage/HepG2): −20–35%
- p65 K310 acetylation (NF-κB; Co-IP/WB): −15–25%
- SIRT1 deacetylase activity (NAD+/AMPK-driven): +15–25%
- 5hmC at HMOX1/NQO1 ARE (TET2; methylation array): +10–20%
- H3K27me3 (EZH2 context; oncogenic models): −10–20%
- Global DNA methylation (%5mC; LUMA/ELISA; chronic inflammation): normalisation ±5–10%
Dosing and Drug Interactions
Epigenetic support/anti-ageing: 5–10g daily long-term; combine with folate/B12 (SAM cycle), NAD+ precursors (NMN/NR; SIRT1 NAD+ substrate). HDAC inhibitors (vorinostat/romidepsin; oncology): Spirulina SIRT1 (class III HDAC) activation is distinct from class I/II HDAC inhibition by these drugs; no direct conflict; may complement by adding class III deacetylation to class I/II inhibition. EZH2 inhibitors (tazemetostat; oncology): Spirulina AMPK → EZH2 Thr487 phosphorylation mechanistically complementary to catalytic EZH2 inhibition; additive H3K27me3 reduction possible. DNMT inhibitors (azacitidine/decitabine; haematology): Spirulina TET2 induction (active demethylation) complementary to DNMT inhibitor passive demethylation; no pharmacological conflict. BET bromodomain inhibitors (JQ1; research): Spirulina p300-H3K9ac reduction upstream of BRD4 binding: complementary to BRD4 competitive inhibition by BETi; additive inflammatory gene suppression. Summary: H3K9ac −20–35%, p65-K310ac −15–25%, SIRT1 +15–25%, 5hmC +10–20%; dosing 5–10g daily. NK concern: low.